Mersana Therapeutics (MRSN) Set to Announce Earnings on Wednesday

Mersana Therapeutics (NASDAQ:MRSN) is scheduled to announce its earnings results before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). Mersana Therapeutics had a negative return on equity of 333.91% and a negative net margin of 349.98%. The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $8.72 million. During the same period in the prior year, the company earned ($0.47) EPS. The company’s revenue for the quarter was down 78.3% compared to the same quarter last year. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Price Performance

Mersana Therapeutics stock opened at $2.34 on Thursday. The stock has a market capitalization of $287.07 million, a P/E ratio of -2.69 and a beta of 1.50. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.72 and a current ratio of 2.72. The stock has a fifty day moving average of $1.90 and a 200-day moving average of $2.09. Mersana Therapeutics has a 52 week low of $1.15 and a 52 week high of $6.28.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Robert W. Baird reduced their price target on Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Citigroup reduced their target price on Mersana Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. Finally, Lifesci Capital upgraded shares of Mersana Therapeutics to a “strong-buy” rating in a report on Monday, July 29th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Insider Buying and Selling

In other Mersana Therapeutics news, CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $1.76, for a total transaction of $88,744.48. Following the transaction, the chief executive officer now directly owns 116,327 shares in the company, valued at approximately $204,735.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 70,849 shares of company stock valued at $129,184 over the last 90 days. Company insiders own 11.80% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.